Plasma salicylate levels and platelet function after acute and chronic administration of slow-release acetylsalicylic acid (Monobeltin).
The relationships between the antiplatelet effects and the pharmacokinetics of a slow release formulation of acetylsalicylic acid (ASA) have been investigated. After acute intake of 750 mg ASA in a slow-release formulation (Monobeltin), a slow increase in plasma ASA was paralleled by a gradual decrease in certain platelet functions. During chronic medication (750 mg twice daily), ASA was present in plasma at all times accompanied by full inhibition of platelet aggregation. For chronic antiplatelet therapy, this slow release formulation of ASA appears to be very effective, unless rapid inhibition of platelet function must be achieved.
D000328:Adult; D001241:Aspirin / Q000008:administration & dosage / Q000097:blood / Q000494:pharmacology*; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D003692:Delayed-Action Preparations; D006626:Hippurates / Q000097:blood; D006801:Humans; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects*; D012459:Salicylates / Q000097:blood*; D020156:Salicylic Acid; D013997:Time Factors
D003692:Delayed-Action Preparations; D006626:Hippurates; D012459:Salicylates; C000693:salicylurate; D020156:Salicylic Acid; D001241:Aspirin